EDIT James M Inhofe sells between 15,001 and 50,000 shares
Jan 01, 2025, 2:45 AM
5.51%
What does EDIT do
Editas Medicine, headquartered in Cambridge, Massachusetts, specializes in genome editing technology and developed a proprietary CRISPR-based platform for transformative genomic medicines. Its lead program, reni-cel, aims to treat sickle cell disease and beta thalassemia.
Senator James M Inhofe sold between 15,001 and 50,000 shares of EDIT on 4 February.
📡️ Health Care
Politician Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.